Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × disitamab vedotin × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Stomach Neoplasms 6 Breast Neoplasms 6 Colorectal Neoplasms 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Non-Muscle Invasive Bladder Neoplasms 2 HER2-positive Gastric Cancer 2 Carcinoma, Transitional Cell 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Muscle Invasive Bladder Carcinoma 1 Muscle Invasive Bladder Cancer (MIBC) 1 Muscle Invasive Bladder Cancer 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 HER2-low Breast Cancer 1 Endometrial Neoplasms 1 Castration-resistant Prostate Cancer 1 Biliary Tract Neoplasms 1

Interventions

Bevacizumab 47 Gemcitabine 46 Cyclophosphamide 43 Carboplatin 37 Docetaxel 36 Fluorouracil 33 Cisplatin 33 Paclitaxel 31 pembrolizumab 30 Oxaliplatin 27 Radiotherapy 25 Irinotecan 25 Capecitabine 25 Leucovorin 23 Dexamethasone 23 Cetuximab 21 Nivolumab 20 Doxorubicin 19 Pemetrexed 18 Drug Therapy 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 14 Lapatinib 14 trametinib 13 fludarabine 13 Sorafenib 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07142200 2025-08-26

DECIDING

RenJi Hospital

Phase 2 Not yet recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡